SCHEMBL5508599

SCHEMBL5508599

CC=CCC1=C(C)CCCC1(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RARB P10826 2/20 0.40
RARG P13631 2/20 0.40
RARA P10276 1/20 0.40
RXRA P19793 1/20 0.40
ALOX5 P09917 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP1A2 P05177 1/20 0.37
HAO1 Q9UJM8 1/20 0.35
TRPA1 O75762 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 2/20 0.33
PTGS1 P23219 1/20 0.33
DRD3 P35462 1/20 0.33
SLCO1B3 Q9NPD5 1/20 0.33
SLCO1B1 Q9Y6L6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9483270 1.00 ALDH1A1 (0.43) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL6942717 0.81 CYP1A2 (0.42) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL3234778 0.81 ALDH1A1 (0.40) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL5510703 0.81 ALDH1A1 (0.40) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL15156575 0.81 ALDH1A1 (0.40) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL11475065 0.79 ALDH1A1 (0.38) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL881427 0.79 CYP1A2 (0.41) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL2706976 0.78 CYP1A2 (0.56) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL2706978 0.78 CYP1A2 (0.56) ALDH1A1GAAMAPTNPSR1RARB
SCHEMBL5696341 0.78 CYP1A2 (0.45) ALDH1A1GAAMAPTNPSR1RARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4073813-A PLATINUM REDUCTION CATALYST, ALDEHYDES, HYDROGEN RHONE-POULENC INDUSTRIES (FR) 1978-02-14 US claimed
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2026-02-19 US disclosed
WO-2025051340-A1 TRPM8 MODULATORS AND RELATED METHOD FOR MODULATING TRPM8 RECEPTORS SYMRISE AG (DE) 2025-03-13 WO disclosed
EP-3247833-A1 IMPROVED FABRIC TREATMENT METHOD FOR STAIN RELEASE Van Buskirk, Gregory (US) 2017-11-29 EP disclosed
CN-104844431-B 1-(2,6,6-trimethyl-cyclohexenyl)-2-buten-1-one preparation method 格林生物科技股份有限公司 2017-01-25 CN disclosed
WO-2016115408-A1 IMPROVED FABRIC TREATMENT METHOD FOR STAIN RELEASE VAN BUSKIRK GREGORY (US) 2016-07-21 WO disclosed
EP-1841850-A1 PERFUME DELIVERY SYSTEM Degussa GmbH (DE) 2007-10-10 EP disclosed
WO-2006079089-A1 PERFUME DELIVERY SYSTEM DEGUSSA GMBH (DE) 2006-07-27 WO disclosed
EP-1605909-A1 FLAVOURED MOUTH WASH COMPOSITION Quest International Services B.V. (NL) 2005-12-21 EP disclosed
WO-2004073671-A1 FLAVOURED MOUTH WASH COMPOSITION QUEST INTERNATIONAL SERVICES B.V. (NL) 2004-09-02 WO disclosed
EP-1383547-A2 AIR FRESHENING COMPOSITIONS, ARTICLES COMPRISING SAME AND METHODS FOR PREPARING SAME THE PROCTER & GAMBLE COMPANY (US) 2004-01-28 EP disclosed
WO-2002089862-A2 AIR FRESHENING COMPOSITIONS, ARTICLES COMPRISING SAME AND METHODS FOR PREPARING SAME THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 WO disclosed
US-4073813-A PLATINUM REDUCTION CATALYST, ALDEHYDES, HYDROGEN RHONE-POULENC INDUSTRIES (FR) 1978-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL RBP4, LRAT, RARB ALDH1A1 156/4885GAA 2228/4885MAPT 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.